Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 2
1998 3
2000 7
2001 5
2002 6
2003 2
2004 2
2005 5
2006 6
2007 6
2008 8
2009 10
2010 7
2011 2
2012 2
2013 2
2014 8
2015 11
2016 7
2017 1
2018 12
2019 8
2020 9
2021 16
2022 17
2023 16
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
Panitumumab-induced trichomegaly.
Sütcüoğlu O, Özet A. Sütcüoğlu O, et al. Among authors: ozet a. Curr Probl Cancer. 2021 Dec;45(6):100748. doi: 10.1016/j.currproblcancer.2021.100748. Epub 2021 Apr 23. Curr Probl Cancer. 2021. PMID: 33933278 No abstract available.
Bone marrow involvement in breast cancer.
Sütcüoğlu O, Özdemir N, Yazıcı O, Özet A. Sütcüoğlu O, et al. Among authors: ozet a. Curr Probl Cancer. 2022 Feb;46(1):100785. doi: 10.1016/j.currproblcancer.2021.100785. Epub 2021 Aug 15. Curr Probl Cancer. 2022. PMID: 34417058 No abstract available.
Brigatinib-induced tuberculosis reactivation: A case report.
Keş V, Sütcüoğlu O, Gürler F, Yazıcı O, Özet A. Keş V, et al. Among authors: ozet a. Curr Probl Cancer. 2021 Dec;45(6):100738. doi: 10.1016/j.currproblcancer.2021.100738. Epub 2021 Apr 10. Curr Probl Cancer. 2021. PMID: 33867154
Current status of biosimilars in Turkey: A survey among medical oncologists.
Gürler F, Kasım DD, Kurt İnci B, Sütçüoğlu O, Ünsal O, Aslan V, Tahtacı G, Özdemir N, Üner A, Günel N, Özet A, Yazıcı O. Gürler F, et al. Among authors: ozet a. J Oncol Pharm Pract. 2022 Oct;28(7):1516-1523. doi: 10.1177/10781552211031643. Epub 2021 Jul 27. J Oncol Pharm Pract. 2022. PMID: 34313505
Thirty-day mortality rates after immunotherapy initiation.
Sütcüoğlu O, İlhan A, Tacar SY, Güven DC, Uçar G, Karadurmuş N, Yıldız F, Eraslan E, Uncu D, Tural D, Üner A, Günel N, Özdemir N, Kılıçkap S, Öksüzoğlu ÖB, Özet A, Yazıcı O. Sütcüoğlu O, et al. Among authors: ozet a. Immunotherapy. 2021 Dec;13(17):1419-1426. doi: 10.2217/imt-2021-0082. Epub 2021 Oct 22. Immunotherapy. 2021. PMID: 34676791
A Case of Cutaneous Diffuse Large B-cell Lymphoma.
Cetin B, Ozet A, Orhan B, Tecimer T. Cetin B, et al. Among authors: ozet a. Turk J Haematol. 2014 Jun;31(2):207-8. doi: 10.4274/tjh.2013.0200. Epub 2014 Jun 10. Turk J Haematol. 2014. PMID: 25035687 Free PMC article. No abstract available.
166 results